ETNB

89bio, Inc. [ETNB] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ETNB Stock Summary

Top 10 Correlated Stocks

ETNB


In the News

10:31 01 Apr 2023 ETNB

Ra Capital Management Now Owns 18% of 89bio

Fintel reports that Ra Capital Management has filed a 13D/A form with the SEC disclosing ownership of 12.88MM shares of 89bio Inc (ETNB).

09:02 01 Apr 2023 ETNB

Tech Stocks Are Surging

The Nasdaq 100 is on a tear

11:40 01 Apr 2023 ETNB

A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH

NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015 to 27 million in 2030.

10:11 01 Apr 2023 ETNB

89bio Announces Upsized Pricing Of $275 Million Common Stock Public Offering

89bio announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25 The post 89bio Announces Upsized Pricing Of $275 Million Common Stock Public Offering appeared first on Pulse 2.0.

10:57 01 Apr 2023 ETNB

Why Shares of 89bio Soared This Week

89bio's lead therapy pegozafermin is seen as a treatment for NASH and hypertriglyceridemia. No NASH drug has been approved yet by the FDA.

07:21 01 Apr 2023 ETNB

89bio's public stock offering upsized by 38%, priced at a 4% discount

89bio Inc. ETNB, +23.83% said Friday that its public offering of stock, which the biopharmaceutical company launched after a 55% surge in its stock in the past two days, was upsized by about 38%. The company said it sold 16.92 million common shares at $16.25 each, to raise $275.0 million.

03:14 01 Apr 2023 ETNB

89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study

Data from a phase IIb study showed that treatment with 89bio's (ETNB) lead candidate improved fibrosis improved fibrosis at 3.5 times the rate of the placebo without worsening NASH.

10:49 01 Apr 2023 ETNB

Biotech Stock Surges on Mid-Stage Drug Trial Success

The shares of 89bio Inc   ( NASDAQ:ETNB) are up 38.2% to trade at $15.11 at last check, after the biotech name revealed its experimental drug pegozafermin to treat nonalcoholic steatohepatitis (NASH) -- a type of fatty liver disease -- met the main objectives of a mid-stage study.

09:30 01 Apr 2023 ETNB

Why Is 89bio (ETNB) Stock Up 34% Today?

89bio (NASDAQ: ETNB ) stock is taking off on Wednesday after the company posted results from a Phase 2b clinical trial. The goal of this study is to determine the effectiveness of pegozafermin in treating patients with NASH.

09:14 01 Apr 2023 ETNB

89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease

Small biotech company 89bio scored a win Wednesday in fatty liver disease, and ETNB stock rocketed well above its 50-day moving average. The post 89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease appeared first on Investor's Business Daily.

ETNB Financial details

Company Rating
Neutral
Market Cap
795.47M
Income
-102.03M
Revenue
0
Book val./share
4.36
Cash/share
5.41
Dividend
-
Dividend %
-
Employees
41
Optionable
No
Shortable
Yes
Earnings
09 May 2023
P/E
-6.94
Forward P/E
-
PEG
-4.2
P/S
-
P/B
4.72
P/C
2.82
P/FCF
-9.67
Quick Ratio
5.62
Current Ratio
5.81
Debt / Equity
0.3
LT Debt / Equity
0.13
-
-
EPS (TTM)
-5.22
EPS next Y
-
EPS next Q
-
EPS this Y
-34.6%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
278.95%
-
-
-
-
SMA20
11.52%
SMA50
37.18%
SMA100
65.58%
Inst Own
98.23%
Inst Trans
-1.77%
ROA
-52%
ROE
-90%
ROC
-0.62%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
52.23M
Shs Float
39.05M
-
-
-
-
Target Price
-
52W Range
2.0-18.03
52W High
-15.39%
52W Low
+661.5%
RSI
55.52
Rel Volume
1.26
Avg Volume
2.07M
Volume
2.6M
Perf Week
11.33%
Perf Month
11.82%
Perf Quarter
84.83%
Perf Half Y
164.41%
-
-
-
-
Beta
0.752094
-
-
Volatility
0.7%, 1.45%
Prev Close
2.28%
Price
15.23
Change
-3.73%

ETNB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
00000
Net income per share
-7.6-24.49-3.08-5.6-2.93
Operating cash flow per share
-5.86-10.86-2.87-4.77-2.33
Free cash flow per share
-5.88-10.92-2.88-4.78-2.33
Cash per share
5.2839.8212.729.375.41
Book value per share
-7.5538.3712.627.834.36
Tangible book value per share
-7.5538.3712.627.834.36
Share holders equity per share
-7.5538.3712.627.834.36
Interest debt per share
0001.210.07
Market cap
44.25M61.63M392.06M210.27M443.08M
Enterprise value
33.01M-31.71M293.88M177.23M388.18M
P/E ratio
-2.74-1.07-7.92-2.33-4.34
Price to sales ratio
00000
POCF ratio
-3.55-2.42-8.48-2.74-5.46
PFCF ratio
-3.54-2.41-8.46-2.74-5.46
P/B Ratio
-2.760.691.931.672.92
PTB ratio
-2.760.691.931.672.92
EV to sales
00000
Enterprise value over EBITDA
-2.050.55-5.94-1.97-3.84
EV to operating cash flow
-2.651.25-6.35-2.31-4.79
EV to free cash flow
-2.641.24-6.34-2.31-4.79
Earnings yield
-0.37-0.93-0.13-0.43-0.23
Free cash flow yield
-0.28-0.42-0.12-0.37-0.18
Debt to equity
-1.710.060.040.290.3
Debt to assets
2.410.060.040.220.23
Net debt to EBITDA
0.71.631.980.370.54
Current ratio
2.61725.918.297.97
Interest coverage
0000-53.2
Income quality
0.770.440.930.850.79
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.01000
Capex to revenue
00000
Capex to depreciation
-6.5-8.18-2.1-0.80.01
Stock based compensation to revenue
00000
Graham number
35.94145.4229.5531.4116.96
ROIC
1.20.29-3.9-1.77-1.39
Return on tangible assets
-1.42-0.6-0.23-0.55-0.52
Graham Net
-7.6137.4212.227.14.11
Working capital
6.96M89.72M202.09M142.45M171.47M
Tangible asset value
-16.06M89.94M202.96M125.96M151.83M
Net current asset value
-16.11M89.72M202.09M125.52M151.09M
Invested capital
0000.150
Average receivables
00000
Average payables
01.25M1.53M4.45M9.67M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
1.01-0.64-0.24-0.72-0.67
Capex per share
-0.02-0.06-0.0100

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-12-312022-03-312022-06-302022-09-30 2022-12-31
Revenue per share
00000
Net income per share
-1.3-1.26-1.23-0.57-2.16
Operating cash flow per share
-1.39-1.2-0.73-0.31-1.9
Free cash flow per share
-1.4-1.2-0.73-0.31-1.9
Cash per share
7.446.26.854.095.41
Book value per share
6.225.053.943.234.36
Tangible book value per share
6.225.053.943.234.36
Share holders equity per share
6.225.053.943.234.36
Interest debt per share
0.960.960.970.420.07
Market cap
264.82M76.68M65.53M273.6M443.08M
Enterprise value
231.79M41.26M24.57M221.22M388.18M
P/E ratio
-2.52-0.75-0.65-2.55-1.47
Price to sales ratio
00000
POCF ratio
-9.38-3.15-4.42-18.47-6.69
PFCF ratio
-9.37-3.15-4.42-18.47-6.68
P/B Ratio
2.10.750.821.792.92
PTB ratio
2.10.750.821.792.92
EV to sales
00000
Enterprise value over EBITDA
-8.78-1.62-0.98-8.26-5.23
EV to operating cash flow
-8.21-1.7-1.66-14.93-5.86
EV to free cash flow
-8.2-1.69-1.66-14.93-5.86
Earnings yield
-0.1-0.33-0.38-0.1-0.17
Free cash flow yield
-0.11-0.32-0.23-0.05-0.15
Debt to equity
0.290.320.840.310.3
Debt to assets
0.220.240.460.240.23
Net debt to EBITDA
1.251.391.641.960.74
Current ratio
8.297.365.455.817.97
Interest coverage
0000-39.13
Income quality
1.070.950.590.550.88
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-1.29-0.330.0600.01
Stock based compensation to revenue
00000
Graham number
13.4711.9510.456.4214.56
ROIC
-0.51-1.16-1.15-0.65-1.02
Return on tangible assets
-0.16-0.19-0.17-0.13-0.38
Graham Net
5.644.583.533.084.11
Working capital
142.45M117.01M119.67M165.43M171.47M
Tangible asset value
125.96M102.74M80.19M152.58M151.83M
Net current asset value
125.52M102.39M79.16M151.85M151.09M
Invested capital
0.150.190.250.130
Average receivables
00000
Average payables
9.68M5.63M4.66M9.53M13.33M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.21-0.25-0.31-0.18-0.5
Capex per share
00000

ETNB Frequently Asked Questions

What is 89bio, Inc. stock symbol ?

89bio, Inc. is a US stock , located in San francisco of Ca and trading under the symbol ETNB

What is 89bio, Inc. stock quote today ?

89bio, Inc. stock price is $15.23 today.

Is 89bio, Inc. stock public?

Yes, 89bio, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap